NCT00982046

Brief Summary

The purpose of this study was to evaluate the clinical performance of three differing contact lens care solutions when used in conjunction with three contact lenses.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2009

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2009

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

September 18, 2009

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 22, 2009

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2010

Completed
Last Updated

November 16, 2016

Status Verified

July 1, 2012

Enrollment Period

1.1 years

First QC Date

September 18, 2009

Last Update Submit

November 15, 2016

Conditions

Keywords

contact lensesdisinfection solutionscontact lens care

Outcome Measures

Primary Outcomes (6)

  • Modulus

    Modulus is a measure of the stiffness of a contact lens material. Modulus is determined from the slope of the stress-strain curve created during tensile tests conducted on a sample of the material. Modulus is measured in mega Pascals (MPa). A higher modulus indicates a stiffer contact lens.

    2 weeks

  • Bulbar hyperemia

    Bulbar hyperemia is the injection (or redness) of the blood vessels in the tissues overlaying the white of the eye. Bulbar hyperemia is measured on a 0-4 scale, with 0=none, 1=trace, 2=mild, 3=moderate, and 4=severe. Half-grades are allowed.

    2 weeks

  • Corneal staining type

    An ophthalmic dye is used to highlight dead or degenerated corneal epithelial cells. The type of staining is measured over the five sectors of the cornea on a 0-4 scale, where 0=none, 1=micropunctate, 2=macropunctate, 3=coalesced macropunctate, and 4=patch (1mm). The five sectors are averaged to give a single score.

    2 weeks

  • Upper palpebral roughness

    The roughness of the inner lining of the upper eyelid is measured on a 0-4 scale, where 0=uniform appearance, 1=trace, 2=mild, 3=moderate, and 4=severe. Half grades are allowed.

    2 weeks

  • High contrast visual acuity

    High contrast visual acuity is a measure of the clearness of vision with full room illumination. Visual acuity is measured with a computer-generated, high contrast logMAR (logarithm minimum angle of resolution) chart.

    2 weeks

  • End of day comfort

    As assessed by the subject as a measure of the comfort of the contact lenses at the end of an average day. End of day comfort is recorded on an 11-point scale where 0=poor and 10=excellent.

    2 weeks

Study Arms (3)

ACUVUE OASYS

ACTIVE COMPARATOR

Acuvue Oasys contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.

Device: Opti-Free RepleniSH multi-purpose disinfecting solutionDevice: ReNu MultiPlus multi-purpose solutionDevice: Clear Care cleaning and disinfecting systemDevice: Senofilcon A contact lens (ACUVUE OASYS)

AIR OPTIX AQUA

ACTIVE COMPARATOR

Air Optix Aqua contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.

Device: Opti-Free RepleniSH multi-purpose disinfecting solutionDevice: ReNu MultiPlus multi-purpose solutionDevice: Clear Care cleaning and disinfecting systemDevice: Lotrafilcon B contact lens (AIR OPTIX AQUA)

Biofinity

ACTIVE COMPARATOR

Biofinity contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.

Device: Opti-Free RepleniSH multi-purpose disinfecting solutionDevice: ReNu MultiPlus multi-purpose solutionDevice: Clear Care cleaning and disinfecting systemDevice: Comfilcon A contact lens (Biofinity)

Interventions

Contact lens solution CE-marked for intended use.

Also known as: Opti-Free® RepleniSH®
ACUVUE OASYSAIR OPTIX AQUABiofinity

Contact lens solution CE-marked for intended use.

Also known as: ReNu® MultiPlus®
ACUVUE OASYSAIR OPTIX AQUABiofinity

Contact lens care system CE-marked for intended use.

Also known as: Clear Care®
ACUVUE OASYSAIR OPTIX AQUABiofinity

Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.

Also known as: ACUVUE® OASYS™
ACUVUE OASYS

Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.

Also known as: AIR OPTIX® AQUA
AIR OPTIX AQUA

Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.

Also known as: Biofinity®
Biofinity

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Signed informed consent.
  • Adapted contact lens wearer for at least one month.
  • Spherical prescription range between +6.00 to -8.00 diopters.
  • Astigmatism of less than or equal to 1.00 diopter in at least one eye.
  • Normal eyes with no evidence of abnormality or disease.

You may not qualify if:

  • Rigid Gas Permeable (RGP) contact lens wear in last 30 days.
  • Concurrent ocular medication, systemic illness, or medical treatment that will affect ocular physiology, lens performance, or vision.
  • Corneal infiltrates, scarring, or neovascularization within central 4 millimeters of cornea.
  • Eye injury or surgery within 8 weeks prior to study.
  • Aphakia, amblyopia, abnormal lacrimal secretions, ocular irritation, keratoconus, corneal irregularity, pregnancy, lactating, planning to become pregnant during the study, and participation in a concurrent clinical trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Visioncare Research Ltd.

Farnham, Surrey, GU9 7EN, United Kingdom

Location

Related Publications (1)

  • Program No 105358. Hall LA, Garofalo R, Young G. Clinical comparison of three contact lens systems in conjunction with senofilcon A, lotrafilcon B and comfilcon A daily wear lenses. American Academy of Optometry 2010.

    RESULT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 18, 2009

First Posted

September 22, 2009

Study Start

April 1, 2009

Primary Completion

May 1, 2010

Study Completion

May 1, 2010

Last Updated

November 16, 2016

Record last verified: 2012-07

Locations